麦(罗ozogamicin)治疗肝venoocclusive疾病患者没有接受了干细胞移植。

文章的细节

引用

复制到剪贴板

贾尔斯FJ, Kantarjian嗯,Kornblau SM,托马斯哒,Garcia-Manero G, Waddelow助教,大卫CL,表象,柯尔伯恩·德·拉希德,Estey呃

麦(罗ozogamicin)治疗肝venoocclusive疾病患者没有接受了干细胞移植。

癌症。2001年7月15日,92(2):406 - 13所示。

PubMed ID

11466696 (在PubMed

]

文摘

背景:麦(Wyeth-Ayerst实验室、圣大卫、PA)的品牌名称是calicheamicin-conjugated人性化anti-CD33单克隆抗体(罗ozogamicin cma - 676)和最近被批准用于治疗老年患者复发的一个子集急性髓系白血病(AML)。麦与发病率约20% 3或4级高胆红素血和肝脏transaminitis患者人群。肝venoocclusive疾病(VOD)一直在报道病人在接受干细胞移植(SCT)麦治疗后。SCT以外的设置,视频点播很少与细胞毒性治疗有关。方法:作者评估了VOD的发病率在119年患者接受Mylotarg-containing non-SCT方案。视频点播是诊断通过使用标准的西雅图和巴尔的摩的标准。结果:一群119(61以前未经治疗的58与复发疾病)AML患者(92例),先进的骨髓增生异常综合征(25例),或慢性骨髓性白血病在爆炸阶段(2例),收到Mylotarg-based方案。14(12%)开发的视频点播。视频点播的诊断是由2患者的组织学和影像学研究10个病人。5(36%)的患者14 VOD antileukemic之前没有收到任何细胞毒性治疗,其中2例接受单麦治疗。 CONCLUSIONS: Mylotarg was shown to be associated with the development of potentially fatal VOD in patients with leukemia who had not received SCT. VOD occurred when Mylotarg was used either as a single agent or when it was given with other cytotoxic agents. VOD occurred in Mylotarg-treated patients who had received no prior cytotoxic therapy. The current study concluded that risk factors for VOD should be assessed when considering Mylotarg therapy, and that attempts to avoid and treat VOD are warranted in patients who receive Mylotarg therapy.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

罗塔ozogamicin